<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="124513">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02078973</url>
  </required_header>
  <id_info>
    <org_study_id>SAFA-1-2014</org_study_id>
    <secondary_id>2013-003800-38</secondary_id>
    <nct_id>NCT02078973</nct_id>
  </id_info>
  <brief_title>Effect of the Diuretic Tolvaptan on Nitric Oxide System. A Dose-response Study (DOVA)</brief_title>
  <acronym>DOVA</acronym>
  <official_title>The Effects of Tolvaptan on Renal Handling of Water and Sodium, Vasoactive Hormones and Circulatory System, During Basal Conditions and During Inhibition of the Nitric Oxide System in Healthy Subjects. A Dose-response Study.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Regional Hospital Holstebro</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Aarhus University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Regional Hospital Holstebro</source>
  <oversight_info>
    <authority>Denmark: Danish Medicines Agency</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Tolvaptan is a selective vasopressin receptor antagonist (V2R) that increases free water and
      sodium excretion. Inhibition of V2R increases vasopressin concentration in plasma, which
      stimulates V1-receptors in the vascular bed and may change both central and brachial
      hemodynamics and plasma concentration of vasoactive hormones.

      The purpose of  the study is to measure the effects of tolvaptan on renal handling of water
      and sodium, systemic hemodynamics and vasoactive hormones at baseline and during nitric
      oxide (NO)-inhibition with L-NG-monomethyl-arginine (L-NMMA).
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>February 2014</start_date>
  <primary_completion_date type="Anticipated">July 2015</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>CH2O</measure>
    <time_frame>5-6 Hours</time_frame>
    <safety_issue>No</safety_issue>
    <description>Measurement of H2O clearance at baseline, during and after L-NMMA infusion</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Urine biomarkers(Aquaporins and Epithelial Sodium Channels Î³)</measure>
    <time_frame>5-6 Hours</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Central and brachial blood pressure</measure>
    <time_frame>5-6 Hours</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Augmentation Index</measure>
    <time_frame>5-6 Hours</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vasoactive Hormones( Angiotensin II, Aldosterone, Endothelin, Atrial Natriuretic Peptide, Brain Natriuretic Peptide, Arginin Vasopressin)</measure>
    <time_frame>5-6 Hours</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fractional sodium excretion</measure>
    <time_frame>5-6 Hours</time_frame>
    <safety_issue>No</safety_issue>
    <description>Measurement of Sodium excretion at baseline, during and after L-NMMA infusion.</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">22</enrollment>
  <condition>Nephropathy</condition>
  <arm_group>
    <arm_group_label>15 mg tolvaptan</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Oral administration of 15 mg tolvaptan on each examination day.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>30 mg tolvaptan</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Oral administration of 30 mg tolvaptan on each examination day.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>45 mg tolvaptan</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Oral administration of 45 mg tolvaptan on each examination day.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Oral administration of a Unikalk tablet</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>15 mg tolvaptan</intervention_name>
    <description>15 mg pr day for 1 day</description>
    <arm_group_label>15 mg tolvaptan</arm_group_label>
    <other_name>Samsca</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>30 mg tolvaptan</intervention_name>
    <description>30 mg pr day for 1 day</description>
    <arm_group_label>30 mg tolvaptan</arm_group_label>
    <other_name>Samsca</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>45 mg tolvaptan</intervention_name>
    <description>45 mg pr day for 1 day</description>
    <arm_group_label>45 mg tolvaptan</arm_group_label>
    <other_name>Samsca</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>1 tablet Unikalk pr day for 1 day</description>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>Unikalk</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Men and women, age 18-40 years

          -  Body Mass Index (BMI) 18,5-30 kg/m2

        Exclusion Criteria:

          -  Anamnestic or clinical signs of heart, lung, lever, kidney and brain disease

          -  Neoplastic disease

          -  Drug abuse

          -  Alcohol abuse

          -  Medical treatment except peroral anticontraceptive

          -  Pregnancy

          -  Smoking

          -  Abnormal blood and urine sample

          -  Abnormal ECG

          -  Blood donation within a month before examination

          -  Arterial hypertension (&gt;140 mmHg systolic and/or 90 mmHg diastolic)
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Frank H Mose, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of medical research</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Safa Therwani, MB</last_name>
    <phone>+45 31515473</phone>
    <email>safatherwani@hotmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Frank H. Mose H Mose, MD, PhD</last_name>
    <phone>+45 78436589</phone>
    <email>frank.holden.christense@vest.rm.dk</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Department of medical research</name>
      <address>
        <city>Holstebro</city>
        <zip>7500</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Frank H Mose, MD, PhD</last_name>
      <phone>+45 78436589</phone>
      <email>frank.holden.christense@vest.rm.dk</email>
    </contact>
    <investigator>
      <last_name>Safa Therwani, MB</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <verification_date>March 2014</verification_date>
  <lastchanged_date>March 1, 2014</lastchanged_date>
  <firstreceived_date>March 1, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Regional Hospital Holstebro</investigator_affiliation>
    <investigator_full_name>Erling Bjerregaard Pedersen</investigator_full_name>
    <investigator_title>Professor, MD, Dr.Sci.</investigator_title>
  </responsible_party>
  <keyword>Tolvaptan</keyword>
  <keyword>L-NMMA</keyword>
  <keyword>Healthy subjects</keyword>
  <keyword>Nephrology</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Kidney Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Nitric Oxide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
